Thermo Fisher Scientific Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $331.0M | $306.0M | $291.0M | $227.0M | $256.0M | $276.0M | $304.0M | $291.0M |
| Amortization | $485.0M | $430.0M | $436.0M | $435.0M | $430.0M | $429.0M | $438.0M | $449.0M |
| Stock-Based Compensation | $82.0M | $83.0M | $84.0M | $70.0M | $81.0M | $75.0M | $79.0M | $68.0M |
| Net Cash from Operating Activities | $2.13B | $1.19B | $3.46B | $2.24B | $1.40B | $723.0M | $3.29B | $2.17B |
| Investing Activities | ||||||||
| Capital Expenditures | $450.0M | $376.0M | $465.0M | $404.0M | $294.0M | $362.0M | $480.0M | $272.0M |
| Business Acquisitions | $0 | $8.87B | $0 | $4.04B | $0 | $0 | $0 | $3.13B |
| Net Cash from Investing Activities | $164.0M | $-8.96B | $891.0M | $-4.12B | $-288.0M | $-527.0M | $20.0M | $-3.58B |
| Financing Activities | ||||||||
| Dividends Paid | $175.0M | $162.0M | $162.0M | $163.0M | $162.0M | $149.0M | $149.0M | $150.0M |
| Stock Repurchases | $1.00B | $3.00B | $37.0M | $963.0M | $0 | $2.00B | $1.00B | $0 |
| Net Cash from Financing Activities | $-1.57B | $1.09B | $3.53B | $-632.0M | $-991.0M | $-102.0M | $-3.67B | $-1.19B |
| Net Change in Cash | $817.0M | $-6.60B | $7.87B | $-2.59B | $431.0M | $132.0M | $-630.0M | $-2.43B |
| Free Cash Flow | $1.68B | $816.0M | $2.99B | $1.84B | $1.11B | $361.0M | $2.81B | $1.89B |